Budget and health impact of switching eligible patients with atrial fibrillation to lower- dose dabigatran

Tanja Fens*, Lisa de Jong, Bregt Kappelhoff, Cornelis Boersma, Maarten J. Postma

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Fingerprint

Dive into the research topics of 'Budget and health impact of switching eligible patients with atrial fibrillation to lower- dose dabigatran'. Together they form a unique fingerprint.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science